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Abstract 
Breast Cancer Associated gene 2 (BCA2) is an E3 ubiquitin ligase that is over-expressed 
in >50% of primary breast cancers, and has been shown to increase in vitro cell 
proliferation and invasion. The protein has been linked to alterations in EGFR 
degradation, however there is some dispute as to its role and influence on the biology of 
this receptor. Our work aimed to ascertain the role of BCA2 in EGFR endocytosis and 
down-regulation and to examine its links with breast cancer outcome. Data generated 
with the online expression analysis tool KM-Plotter showed that high BCA2 levels are 
associated with poor prognosis in ovarian, gastric and breast cancer, particularly HER2 
over-expressing breast cancers. Experimentally, we demonstrate that over-expression of 
BCA2 induced a reduction in total EGFR levels. BCA2 over-expressing cells stimulated 
with EGF exhibited reduced lysosomal degradation of both this ligand and its receptor. 
Signalling downstream of EGFR in BCA2 over-expressing cells was characterized by a 
lower magnitude but increased duration. Our findings support a role for BCA2 in receptor 
endocytosis. Consistent with this we show that BCA2 over-expression reduces the level 
of vesicle-associated Rab7, a regulator of late endocytosis and documented interaction 
partner of BCA2. Levels of transferrin receptor and the uptake of transferrin were 
unaltered by over-expression of BCA2 indicating that trafficking changes may be limited 
to late endocytic sorting events. This report offers a thorough exploration of BCA2 
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biology and suggests a context-dependent role for the protein in the endocytic regulation 
of EGFR and as a prognostic biomarker in cancer.  
Introduction 
Receptor tyrosine kinases (RTKs) are essential for normal cell function and are often 
over-expressed, ineffectively down-regulated or mutated in cancer. Epidermal growth 
factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) are 
members of the ErbB family of RTKs that are of particular importance in breast cancer. 
Although estimates vary, EGFR over-expression is thought to present in approximately 
30% of breast cancers while HER2 positivity is detected in 25-30% of cases (1, 2). High 
levels of EGFR and HER2 are associated with more aggressive cancer phenotypes and 
poorer prognosis (3). When activated by ligand binding and dimerization, RTKs are 
internalized and pro-oncogenic intracellular signalling is initiated, primarily via the MAPK 
and PI3K/Akt pathways. The aberrant gene expression induced by enhanced 
expression/activation of EGFR or HER2 promotes cancer cell proliferation, survival, 
migration, and angiogenesis (4).  
Endocytosis is the mechanism by which cells internalize ligand-bound RTKs, and a critical 
process for the regulation of downstream signalling (5).  Activated receptors are 
removed from the cell surface in vesicles that are shuttled into the cell. These vesicles 
fuse with early endosomes via the action of Rab5, a member of the Rab family of small 
GTPases that collectively coordinate many stages of membrane trafficking. Receptors are 
sorted in the early endosome and are subsequently trafficked along different routes (6): 
fast or slow recycling to the plasma membrane or lysosomal degradation. Receptor 
recycling maintains receptor numbers on the cell surface, prolongs signalling and 
promotes receptor reactivation. Rab7 controls the degradation pathway and is 
responsible for receptor sorting in late endosomes and transport to lysosomes for 
degradation (7). 
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Proteins regulating RTK endocytosis have also been implicated in cancer (8) including 
Rab7 (9), Rab5 (10) and the E3 ligase C-cbl (11, 12). Rab7 has been shown to affect cell 
survival and adhesion via co-ordination of the later stages of endocytosis (9). Rab7 has 
additionally been shown to have a role in endocytosis and cancer through its interaction 
with Breast Cancer Associated gene 2 (BCA2). The consequence of the relationship 
between BCA2 and Rab7 has been separately said to both inhibit and promote EGFR 
degradation (13-15).  
BCA2 is a RING E3 ubiquitin ligase, a family of enzymes involved in the post-
translational modification of other proteins via the addition of small, regulatory ubiquitin 
tags. In addition to BCA2, a number of E3 ligases have been implicated in breast cancer 
including: BRCA1; RNF11; c-Cbl and Efp (16).  Upon first identification, BCA2 was 
named Rabring7 due to its interaction with Rab7 (13). The protein is also known as 
RNF115 and ZNF364 and the name BCA2 derives from its association with breast cancer. 
Differential display and subtractive hybridization screening in normal and malignant 
mammary cell lines showed that BCA2 was significantly up-regulated in 56% of primary 
breast cancers and 74% of estrogen receptor (ER) positive disease (17). In vitro data 
from the same study suggested an oncogenic role: siRNA depletion of BCA2 significantly 
reduced cell growth and invasion of T47D (ER+) breast cancer cells while over-expression 
of BCA2 in NIH3T3 (mouse fibroblast) cells increased proliferation by 50%. Further 
functional links between BCA2 expression and breast cancer pathology have since been 
explored by other in vitro experiments, clinical expression analyses and genomic studies. 
The principal findings from these studies indicate that BCA2: 1) is transcriptionally 
regulated by the ER, 2) can modulate the anti-breast cancer effect of the AMPK inhibitor 
metformin, 3) can promote proliferation of ER+ breast cancer by down-regulating p21, 4) 
has a role in regulating the DNA damage response, 5) is a potential susceptibility gene 
for breast cancer and 6) may serve as a potential drug target in anti-breast cancer 
therapy (18-24).  
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It has been suggested, based on over-expression studies, that BCA2 is recruited by Rab7 
to late endosomes and lysosomes, and that as a result EGFR degradation is inhibited 
(13). Intriguingly, BCA2 has also been shown to promote degradation of EGFR, as siRNA 
depletion of BCA2 in cervical cancer cells caused EGFR to accumulate in late endocytic 
compartments following EGF stimulation. The defects in EGFR degradation were 
attributed to a reduction in the number of late endosomes formed in the BCA2 depleted 
cells (15).  
As the body of work on BCA2 has increased, so too has the apparent disparity in the 
literature surrounding the protein’s role in receptor trafficking and breast cancer. We 
therefore sought to further explore BCA2’s role in EGFR endocytosis, down-regulation 
and signalling. In parallel we also examined the relationship between BCA2 expression 
and patient survival in different breast cancer subtypes and in other cancers. Our results 
substantiate a role for BCA2 in EGFR endocytosis and signalling and link this to the sub-
cellular localization of Rab7. BCA2 expression correlates with poorer prognosis in 
ovarian, gastric and breast cancers (particularly in breast cancer subtypes that over-
express HER2).  
 
Materials and Methods  
Routine cell culture 
MCF-7 (ER+, HER2-), MDA-MB-231 (ER-, HER2-), BT474 (ER+, HER2+) and T47D (ER+, 
HER2-) human breast cancer cells were kindly donated by the Breast Cancer Molecular 
Pharmacology Group (BCMPG), Cardiff University. MCF-10A human breast epithelial cells 
were purchased from the ATTC’s approved UK supplier LGC Standards. Cervical cancer 
HeLa cells were obtained from the European Molecular Biology Laboratory (25).  
MCF-7, MDA-MB-231, BT474 and T47D cells were cultured in Roswell Park Memorial 
Institute media (RPMI) containing phenol red and supplemented with 10% Fetal Bovine 
Serum (FBS). MCF-10A cells were grown in Dulbecco's Modified Eagle Medium: Nutrient 
mixture F12 (DMEM/F12) supplemented with 5% horse serum, 20 ng/mL epidermal 
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growth factor (EGF), 0.5 µg/mL hydrocortisone, 100 ng/mL cholera toxin and 10 µg/mL 
insulin (26). HeLa cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) 
supplemented with 10% FBS.  
All cell lines were cultured at 37°C in a 5% CO2 humidified atmosphere. Cells were used 
up to a maximum of 28 passages and were subject to regular mycoplasma testing. 
Transfection  
Plasmid constructs  
The pCMV-HA plasmid containing the BCA2 insert was a kind gift from Naoki Yamamoto 
at the AIDS Research Centre, National Institute of Infectious Diseases, Tokyo (27).  
pCMV6-AC-HA (PrecisionShuttle) with no insert DNA was used as a mock-transfection 
control in HA-BCA2 experiments.  
Fugene 6 transfection  
The following method describes volumes and quantities per well of a 12-well plate and 
quantities were scaled accordingly for transfections in 6- and 96- well plates. MCF-7 
(110,000), MDA-MB-231 (75,000) or HeLa (67,000) cells were seeded onto coverslips 
and incubated for 24 hr in 800 µL complete media. After 24 hr the cells were transfected 
with Fugene 6 (#E2691, Promega) in accordance with the manufacturer’s directions. 
Fugene 6 transfection mixture was prepared by mixing 3 µL of Fugene 6 with 97 µL of 
serum free media (SFM) and incubating at room temperature for 5 min. The diluted 
Fugene 6 was then added to 1 µg of plasmid DNA in 98 µL of SFM. The mixture was 
incubated at room temperature for 30 min then 200 µL of the FuGENE 6:DNA complex 
was added dropwise to cells. The media was changed for fresh complete media after 5 hr 
and cells were subject to analysis 24 hr after transfection. 
Ligand Binding and Uptake: EGF, Alexa-labeled-EGF and Alexa-labeled-
Transferrin  
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Transfected cells were pre-incubated in 1 mL SFM for 1 hr at 37°C, 5% CO2. The SFM 
was then replaced with 500 µL of SFM containing one of the following ligands diluted in 
SFM: 20 ng/mL EGF (#E9644, Sigma); 8 µg/mL transferrin Alexa-488 (#T-13342, 
Molecular Probes); 0.5 µg/mL Alexa-555 EGF (#E35350, Molecular Probes); 0.5 µg/mL 
Alexa-488 EGF (#E13345, Molecular Probes). The cells were incubated in these ligand 
solutions for time periods up to 60 min. The culture plates were then placed on ice and 
rinsed 2x with ice-cold PBS prior to further analysis.  
Antibodies 
Western Blotting: 
Mouse anti-HA HA.11 clone 16B12 (#MMS-101P, Covance, 1:1000). Goat anti-BCA2 
(#SAB2500854, Sigma Aldrich, 1:500). Rabbit anti-EGFR (#HPA018530, Sigma, 
1:1000). Mouse anti-Transferrin Receptor (#13-6800, Life Technologies, 1:500). Mouse 
anti-c-Met (#3127, Cell Signalling, 1:500). Rabbit anti-pEGFR Tyr1068 (#3777, Cell 
Signalling, 1,000). Rabbit anti-AKT (#9272, Cell Signalling, 1:1,000). Rabbit anti-pAKT 
Ser473 (#9271, Cell Signalling, 1:500). Rabbit anti-ERK 1/2 (#9102, Cell Signalling, 
1:500). Rabbit anti-pERK 1/2 Thr202/Tyr204 (#9101, Cell Signalling, 1:500). Mouse 
HRP conjugated anti-β-tubulin (#ab21058, Abcam, 1:50,000). All secondary antibodies 
for Western blotting were from Pierce and were used at a dilution of 1:2000. 
Immunofluorescence microscopy (IF): 
Mouse anti-HA HA.11 clone 16B12 (#MMS-101P, Covance, 1:1000). Rabbit anti-EGFR  
(#HPA018530, Sigma, 1:100). Mouse anti-EEA1 (#SC-6415, Santa-Cruz, 1:200).  
Rabbit anti-LAMP2 (#H4B4, DSHB, 1:200).  Rabbit anti-Rab7 (#9367, Cell Signalling, 
1:100). Rabbit anti-HA (#3724, Cell Signalling, 1:1600). Rabbit anti-cathepsin D 
(#ab72915, Abcam, 1:100). Mouse anti-transferrin receptor (#13-6800, Life 
Technologies, 1:300). All secondary antibodies for IF were from Life Technologies and 
were used at a dilution of 1:400. 
Fluorescence microscopy  
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Immunofluorescence 
PFA fixation for antibodies against: HA, EEA1, TfR and EGFR 
Cells cultured on glass coverslips were fixed in 3% paraformaldehyde (PFA) for 15 min, 
free aldehyde groups were blocked with 50 mM NH4Cl for 10 min and cells were 
permeabilised for 5 min with 0.2% Triton X-100.  
Methanol fixation for antibodies against: HA, cathepsin D and LAMP2 
Cells cultured on glass coverslips were fixed in -20 °C, 100% methanol at -20 °C for 5 
min then washed thrice in PBS. 
Single antibody immunolabeling for HA 
Following fixation, a solution of 2% FBS, 2% bovine serum albumin (BSA) in PBS was 
used to block non-specific binding sites via a 1 hr incubation. Cells were then incubated 
for 1 hr with anti-HA antibody diluted in blocking solution before being washed and 
incubated with Alexa labeled secondary antibody and Hoechst 33342 (#H3570, Life 
Technologies) at 1 µg/mL for 1 hr. Washed coverslips were mounted onto glass slides 
and were imaged by confocal microscopy.  
Double antibody immunolabeling for HA and either EGFR, EEA1, cathepsin D, TfR or 
LAMP2 
The protocol for double immunolabeling followed the protocol for single labeling until 
after the secondary antibody incubation. At this point the cells were blocked for a second 
time in 150 µL blocking buffer for 30 min before being incubated with the second diluted 
primary antibody (raised in a different species from either of the previously applied 
antibodies). After incubation for 1 hr at room temperature the coverslips were washed, 
then incubated with the appropriate species of Alexa labeled secondary antibody for 
1 hr. Washed coverslips were then mounted onto glass slides for imaging. 
Double antibody immunolabeling for HA and Rab7 
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The cells were fixed then incubated with NH4Cl as for single labeling. They were then 
blocked in 150 µL of 5% BSA, 0.3% (v/v) Triton X-100 for 1 hr and subsequently 
incubated overnight with anti-Rab7 antibody (4°C with gentle agitation in a humidified 
chamber). The antibody diluent was 1 % BSA, 0.3 % (v/v) Triton X-100. On the second 
day cells were incubated with Alexa labeled secondary antibody and Hoechst 33342 for 
1 hr. The protocol for single antibody labeling for HA was then followed, though Hoechst 
was omitted from the final secondary antibody incubation. 
Microscopy  
Confocal fluorescence microscopy analysis was conducted on a Leica SP5 inverted 
confocal laser scanning microscope. The microscope was equipped with a 63x oil-
immersion objective and 405, 488, 453 and 633 nm excitation lasers. Gain and offset 
settings were optimized for each fluorescent channel within an experiment. Images were 
recorded using the sequential scanning mode to prevent fluorescence channel crosstalk/ 
bleed-through. Images were scanned at 100 Hz with a line average of three to reduce 
noise. 
Western blotting  
Cells were seeded in 6-well plates and grown in complete media to 70-80 % confluence 
on the day of lysate collection. Cell lysates were collected on ice by washing x1 in ice-
cold PBS then scraping in 100 µL of lysis buffer (150 mM NaCl, 50 mM Tris base pH 8, 
1 % NP-40 containing protease and phosphatase inhibitors). The lysates were 
centrifuged at 13,800 xg for 10 min at 4 °C and protein concentration of the 
supernatants was determined by bicinchoninic acid assay (BCA) assay. Samples were 
then mixed with 4x SDS-PAGE loading buffer before thermal denaturation at 96 °C for 
5 min, and centrifugation at 4°C, 13,800 g for 30 s. Proteins (18 µg total) were then 
separated by SDS-PAGE on a 10% acrylamide gel and were transferred to Polyvinylidene 
fluoride (PVDF) membrane. Membranes were blocked for 1 hr at room temperature in 
5% milk in PBST (0.025% Tween20) and were incubated overnight at 4 °C with primary 
antibodies diluted in milk in PBST at the following dilutions: 5 % milk (anti-Tubulin), 3 % 
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milk (anti-BCA2) or 2 % milk (all other primary antibodies). Membranes were washed in 
PBST before being incubated for 1 hr at room temperature with species specific 
secondary antibodies (diluted in 2 % milk in PBST). Before development, the membranes 
were washed again in PBST. Protein bands were detected by enhanced 
chemiluminescence (ECL). Band intensities were quantified using ImageJ software and 
normalized to loading control bands for housekeeping proteins.  
Antibody stripping for membrane reprobing 
After the first immunoblotting procedure had been completed and imaged, some 
membranes needed to be stripped and reprobed, to this end membranes were washed 
2x 5 min in PBS then 2 x 5 min in dH2O. The membranes were then stripped in 0.2 M 
NaOH for 10 min before being washed twice more for 5 min in dH20 and 2 x 5 min in 
PBS. The membrane was then ready for the blocking step of the second immunoblotting 
procedure. 
Cell viability 
Cell viabilities were determined using the CellTiter-Blue® assay (#G8080, Promega) in 
accordance with manufacturer’s instructions. HeLa cells (3,500) were seeded into black 
96-well plates and incubated overnight at 37°C, 5% CO2. The following day they were 
transfected with 0.1 µg HA-BCA2 or empty vector control and incubated under normal 
tissue culture conditions for 24 hr. Cells were then serum starved in SFM for 1 hr before 
being incubated for 48 hr with 100 µL of either: complete media, reduced-serum (0.5% 
FBS) media or reduced-serum media containing 20 ng/ml EGF. After 44 hr incubation, 
20 µL of CellTiter-Blue reagent was added to each of the wells and the plates were 
returned to the incubator for 4 hr. The final fluorescence (544Ex/590Em) was measured 
using a Fluostar Optima fluorescent plate reader. 
Statistical methods 
Results are presented from either all the data from three independent experiments or 
representative images/immunoblots are shown (as indicated in the figures). Where 
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replicates were performed (and data was quantitative) separate means were calculated 
for each independent experiment. Independent means were then averaged to give an 
estimate of the true mean (µ) and 95% confidence intervals. Quantitative data are 
presented as means ± 95% confidence intervals (28). Prior to conducting statistical 
analyses to compare means, F-tests for heteroscedasticity were performed to determine 
whether a T-test for equal or unequal variance should be used. Student’s independent T-
tests were performed when determining the significance of differences between two 
groups/means.  
GOBO: gene expression-based outcome  
The online biomarker assessment tool GOBO (http://co.bmc.lu.se/gobo)(29) was used to 
analyze the expression levels of BCA2 across different subgroups in a panel of 51 breast 
cancer cell lines based on Affymetrix ID 212742_at (BCA2) signal intensity. Mean log2 
expression levels for each cell line were displayed by the software along with box-plots 
for each of the groups (Basal A, Basal B and luminal; Triple negative, HER2, and 
hormone receptor positive). Analysis of variance (ANOVA) statistics were automatically 
performed to assess differences between groups. 
Biomarker and survival analysis  
The KM Plotter online biomarker analysis tool (http://www.kmplot.com/) (30) was used 
to produce Kaplan-Meier plots for relapse free survival (RFS) and overall survival (OS) 
based on the signal intensity of Affymetrix ID 212742_at (BCA2). This probe set was 
chosen for the analysis as JetSet probes have been optimized for gene specificity, splice 
variant coverage and resistance to degradation (31). The dataset was divided into high 
and low expressing groups using the auto-select best cutoff. Survival curves were 
generated across all tumours and, in breast cancer, for analyses restricted according to 
ER status, HER2 status and molecular subtype. The hazard ratio for RFS or OS with 95% 
confidence intervals and logrank P value were also calculated for low vs. high BCA2 
expression. 
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Results 
BCA2 expression in a panel of cell lines  
BCA2 mRNA expression was analyzed in silico from a publicly available dataset of 51 
breast (normal and cancer) cell lines using GOBO (29). Relative expression levels across 
the cell lines are presented in Figure 1A. Statistical comparison was also made between 
groups of cell lines divided according to basal or luminal type (Fig. 1B). A third analysis 
looked at BCA2 expression across cell line groups defined by HER2 positivity, hormone 
receptor positivity and triple negative subtypes (Fig. 1C). Mean BCA2 mRNA levels were 
higher in breast/breast cancer cell lines categorized as luminal (e.g. MCF-7 and T47D) 
though the difference in expression compared with basal A (e.g. MDA-MB-468) and 
basal B (e.g. MDA-MB-231) types was non-significant (Figure 1B, p=0.09616). The 
highest mean BCA2 expression was associated with hormone receptor positivity and 
lower mean BCA2 expression levels were seen in the triple negative and HER2+ cell lines 
(Figure 1C). The difference in BCA2 expression between triple-negative, HER2 and 
hormone receptor positive cell line classes was statistically significant (p=0.02912). 
We compared relative protein expression levels of BCA2 and EGFR in a selection of 
breast cell lines by Western blotting. Band intensities were quantified using ImageJ 
software, normalized to tubulin and expressed relative to MCF-10A levels (Fig. 1D). Our 
cell panel comprised immortalized breast epithelial cells (MCF-10A), luminal A, ER+ 
breast cancer cells (MCF-7 and T47D), triple-negative breast cancer (MDA-MB-231) and 
luminal B, HER2+ breast cancer (BT474). We also included the HeLa cervical carcinoma 
line in our analysis as EGFR trafficking in these cells is well characterized and they have 
been used in published studies of BCA2’s effects on receptor trafficking (15). 
Endogenous BCA2 expression varied across these cell lines (Fig. 1D) and suggested a 
possible inverse relationship between BCA2 and EGFR expression. However, the panel of 
cell lines tested was not sufficiently large to perform meaningful correlation analyses. 
The immunoblots of BCA2 demonstrated two clear bands near the approximate predicted 
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molecular weight of BCA2 (34 kDa). Confirmation that these both represented BCA2 was 
shown using siRNA depletion (supplementary Figure S1). In line with data in Figure 1D, 
BCA2 most often appears in the literature as a doublet (15, 17, 27, 32). T47D and MCF-
7 cells expressed the highest levels of BCA2 while HeLa expressed the lowest. MDA-MB-
231 cells were also found to express relatively high levels, contrary to some published 
data, though in line with others and with the mRNA data in Figure 1A (18, 22).  
Heterogeneity of BCA2 localization and expression levels in transiently 
transfected MCF-7, MDA-MB-231 and HeLa cells  
The sub-cellular localization of endogenous BCA2, using different antibodies, has 
variously been described in the literature as: nuclear (MCF-7) (33); cytoplasmic and/or 
late endosome/ lysosome associated (BHK) (13); punctate cytoplasmic staining (MCF-7) 
(32); faint cytoplasmic and intense nucleolar staining (MCF-7) (21). In transfected 293T 
cells large cytoplasmic accumulations of BCA2 have been demonstrated (27). The 
differences in reported subcellular localization may reflect true biological heterogeneity 
or may result from different experimental approaches. Given these discrepancies and the 
lack of validated commercially available antibodies, we decided to use transient 
expression of epitope tagged protein as an alternative means of characterising BCA2 
localization. 
The HA-BCA2 plasmid was transfected into MCF-7, MDA-MB-231 and HeLa cells which, 
24 hrs later, were fixed and immunolabeled for HA. HA-BCA2 transfected MCF-7 and 
HeLa cells both displayed a number of different, seemingly expression level-dependent 
phenotypes (Fig. 2, top and bottom rows). High BCA2 expressing cells either tended to 
display ubiquitous small, uniform vesicles throughout the cytoplasm or they contained 
large, dense perinuclear vesicles and/or large cytoplasmic structures. Cells expressing 
moderate BCA2 levels cells tended to have diffuse cytoplasmic staining with few sparsely 
distributed vesicles, whilst low HA-BCA2 expressing cells only showed a faint, diffuse 
cytoplasmic labeling. There was some evidence of nuclear labeling in the transfected 
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cells but this was rare (<5% of transfected cells) and there was no evidence of BCA2 in 
nucleoli.  
HA-BCA2 over-expressing MDA-MB-231 cells (Fig. 2, middle row) showed signs of poor 
viability: most of the transfected cells appeared to be rounded or demonstrated 
cytoplasmic vacuolation. Owing to the poor viability no further experiments were 
performed on the MDA-MB-231 cells. 
In order to verify that the sub-cellular localisation in Figure 2 related to HA-tagged 
BCA2, i.e. to confirm that the protein was expressed and the HA-tag was uncleaved, 
double-immunolabeling was performed for BCA2 and HA. Co-localization analysis 
confirmed that immunofluorescence staining was specific to BCA2 and that the HA tag 
remained attached in vitro (Supplementary Figure S2A). Single labeling was also 
performed for both BCA2 and HA (Supplementary Figure S2B). The staining patterns 
seen in single-labeled cells were very similar, further indicating the 
structures/localisation seen were not artefacts of the double-labeling process. These 
experiments also validated the goat anti-BCA2 antibody for use in immunofluorescence.   
BCA2 over-expression decreases EGFR levels in HeLa cells  
BCA2 has been shown to alter EGFR trafficking (13-15) but its effects on basal levels of 
this RTK have not been directly explored. HeLa cells naturally express low levels of BCA2 
(Fig. 1) and EGFR trafficking in these cells has been extensively studied. BCA2 depletion 
in HeLa cells has previously been shown to impair ligand induced degradation of both 
EGFR and c-Met (15). The HeLa cell line was therefore a useful model for studying the 
effects of BCA2 over-expression on EGFR in cancer cells. We investigated BCA2 induced 
changes in total levels of the RTKs EGFR and c-Met and also of the (non-tyrosine kinase) 
transferrin receptor (TfR). Receptor levels were examined by Western blotting of cells 
transfected with HA-tagged BCA2 or the mock plasmid. Three independent, duplicate 
experiments showed a significant decrease in total EGFR (p=0.001) and c-Met 
(p=0.003) in the HA-BCA2 over-expressing cells (Fig. 3A-C); TfR expression was not 
significantly altered (p=0.365. Figures 3A and D).  
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In order to visualize the reduction in EGFR levels induced by BCA2 over-expression, two 
different experiments were performed. Firstly, cells were treated with EGF to induce 
EGFR accumulation in early endosomes and secondly cells were incubated with 
fluorescently labeled EGF on ice (9). Incubating cells with EGF at 4°C for 30 min allows 
the ligand to bind to surface receptors without inducing internalization (34).  
Figure 3E shows the results of double-labeling IF for HA and for EGFR following EGFR 
stimulation. HA-BCA2 transfected cells showed reduced accumulation of EGFR in 
intracellular vesicles. Figure 3F demonstrates a trend of reduced EGF-488 binding to the 
HA-BCA2 over-expressing cells, indicative of reduced receptor numbers on the cell 
surface.  
Total expression levels of EGFR were also examined in MCF-7 cells following siRNA 
depletion of BCA2 in three independent Western blotting experiments (Supplementary 
Fig. S1). An 80% reduction in BCA2 was associated with a 2.5 fold increase in EGFR 
levels in the BCA2high/EGFRlow cell line (p=0.040) while levels of TfR were unaffected 
(p=0.451). This confirms in two different cell types that BCA2 expression can influence 
EGFR protein expression levels. 
BCA2 over-expression delays EGFR degradation in HeLa cells  
The binding of EGF to EGFR stimulates internalization and trafficking of the receptor-
ligand complex, primarily to the lysosomes for degradation (34). BCA2 has been 
reported to alter ligand-induced degradation of EGFR, though there is some debate as to 
whether the protein promotes or inhibits degradation of the receptor (13-15). Having 
shown that total EGFR levels are influenced by changes in BCA2 expression we 
investigated the effect of BCA2 over-expression on EGFR endocytic downregulation 
following EGF stimulation (Fig. 4).  
For Western blot analysis, HA-BCA2 and mock transfected HeLa cells were serum starved 
for 60 min then stimulated with 20 ng/mL EGF (or diluent control) for the same time 
period. Cell lysates were collected from three independent experiments conducted in 
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triplicate. Following SDS-PAGE and transfer to PVDF, immunoblotting was performed for 
EGFR, HA and tubulin (Fig. 4A) and band-densities were quantified using ImageJ (Fig. 
4B). Basal EGFR expression levels (t=0) were significantly reduced in HA-BCA2 over-
expressing cells relative to mock transfected controls (p=0.002). Conversely, after 60 
min, significantly more EGFR persisted in the HA-BCA2 over-expressing cells (p=0.030) 
indicating that EGFR degradation was delayed as a result of the increase in BCA2 levels. 
We next monitored the endocytic degradation of EGFR by confocal microscopy of HA-
BCA2 over-expressing HeLa cells acutely stimulated with fluorescently labeled EGF. To 
control for potential general effects on endocytosis, we also used fluorescently labeled 
transferrin (Tf) in parallel experiments. Transfected cells were incubated for 15 or 
60 min with either 0.5 µg/mL Alexa-488 EGF or 8 µg/mL Alexa-488 Tf. After incubation 
with the fluorescent ligands the cells were fixed and immunolabeled for HA-BCA2 (Fig. 
4C and D).  
Figure 4C demonstrates that EGF internalization was initially reduced in the BCA2 over-
expressing HeLa cells, as indicated by the low EGF-488 signal at 15 min. After 60 min of 
incubation, EGF appeared to accumulate and persist in BCA2 over-expressing HeLa cells. 
In contrast, the majority of the EGF signal was lost in the non-transfected cells due to 
lysosomal delivery and degradation. This mirrors the results seen by Western blotting 
(Fig. 4A). There was little discernible difference in Tf uptake and distribution between 
HA-BCA2 over-expressing cells and non-transfected controls at either time point (Fig. 
4D). 
Endocytic profile of BCA2 over-expressing HeLa with and without EGF  
stimulation 
Having established that EGF degradation was delayed/impaired by HA-BCA2 
over-expression, we sought to determine which endocytic compartments the EGF was 
retained in at the 60 min time point.  We also wanted to ascertain whether the endocytic 
profile of the transfected cells and/or the localization of BCA2 was altered in the EGF 
stimulated (and unstimulated cells). Following 60 min of serum starvation, HA-BCA2 
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over-expressing HeLa cells were either incubated with EGF-555 or diluent control for 
60 min. After fixation, double-immunofluorescence labeling was performed for HA and 
either EEA1 (early endosomes), TfR (recycling endosomes), LAMP2 (late endolysosomes) 
or cathepsin D (lysosomes). Figure 5A-D shows that in both unstimulated (0 min EGF) 
and EGF stimulated (60 min EGF) cells there were no significant alterations in the 
sub-cellular localization or abundance of any of the immunolabelled endolysosomal 
compartments. HA-BCA2 localization remained heterogeneous in EGF stimulated and 
unstimulated cells: vesicles and cytoplasmic accumulations in a range of sizes and/or 
diffuse cytosolic labeling patterns were seen, as in Figure 2. After 60 min incubation, the 
signal from EGF-555 had largely been lost from untransfected cells, indicating 
degradation. In HA-BCA2 over-expressing cells however, EGF-555 accumulation was 
detected in early (EEA1 positive) and late (LAMP2 positive) endosomal compartments 
(Fig. 5A and C red-blue channel merge [RB] insets). Little co-localisation was seen 
between EGF-555 and the cathepsin D positive and TfR containing compartments (Fig. 
5B and D, RB-inset).  
BCA2 over-expression alters downstream EGFR signalling in HeLa cells  
Upon EGF binding and receptor dimerization, the intracellular domain of EGFR becomes 
phosphorylated. This initiates downstream activation of oncogenic signalling, 
predominantly via the MAPK and PI3K/Akt pathways. EGFR is internalized following 
activation and there is a strong body of evidence to indicate that it continues to signal 
from endosomes and that receptor internalization is required for some components of 
downstream signalling (35, 36). We therefore hypothesised that the BCA2 induced 
changes in EGFR trafficking and degradation might alter downstream signalling 
pathways. Three independent experiments were performed to test this hypothesis. HA-
BCA2 or mock transfected HeLa cells were serum starved then stimulated with 20 ng/mL 
of EGF for 5 or 60 min before lysates were collected on ice. No baseline phosphorylation 
of EGFR was observed in unstimulated cells (data not shown) so a 5 min pulse of EGF 
was selected as the earliest time point. Cell lysates were probed for HA and a panel of 
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signalling proteins: total EGFR and phosphorylated EGFR (pEGFR, Tyr1068), total AKT 
and phosphorylated Akt (pAKT, Ser473) and total ERK1/2 and phosphorylated ERK 
(pERK, Thr202/Tyr204). The complete panel of immunoblots shown in Figure 5A was 
achieved by stripping and re-probing of PVDF membranes cut into low and high 
molecular weight strips. Band intensities were quantified using ImageJ software and 
protein activation was determined by the ratio of phosphoprotein to total protein (Fig. 6B 
and C). Activation of EGFR was examined by normalizing pEGFR to total EGFR and to 
Akt. Total Akt also acted as a loading control for pEGFR and thus enabled further 
information to be obtained about the relative proportion of active EGFR while taking into 
account changes in total EGFR levels.  
Quantification and student’s independent two-tailed t-test of the immunoblotting data in 
Figure 6A revealed that after 5 min EGF stimulation there was a significant reduction in 
pEGFR, pAkt and pERK in BCA2 over-expressing HeLa cells compared with mock 
transfected controls (Fig. 6B). Conversely, after 60 min EGF stimulation, significantly 
more EGFR, Akt and ERK remained active in the BCA2 over-expressing cells compared 
with controls (Fig. 6C). Examining the ratios of pEGFR/total EGFR and pEGFR/total AKT 
we found that at 5 min the reduction in EGFR activation in HA-BCA2 over-expressing 
cells was proportional to the reduction in total receptor level. However, after 60 min of 
EGF stimulation, a greater proportion of the remaining EGFR was active in the HA-BCA2 
over-expressing cells. Overall this suggests that BCA2 over-expression can influence the 
endocytic signalling and degradation of EGFR. 
BCA2 over-expression reduces HeLa cell viability  
The above results indicated that BCA2 over-expression elicited a downstream EGFR 
signalling response of reduced magnitude (at 5 min) but prolonged duration (at 60 min). 
We wondered whether these changes in signalling translated to changes in cell growth. 
HA-BCA2 or mock transfected HeLa cells were serum starved for 1 hr, prior to a further 
48 h incubation in either reduced serum media (0.5% FBS), in media supplemented with 
10% FBS or in reduced serum media supplemented with 20 ng/ml EGF. Cell viability was 
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assessed using a Cell-titre blue assay. Data from three independent experiments 
conducted in triplicate were processed by converting mean fluorescence intensity values 
to “cell viability” as a percentage of mock-transfected controls grown in complete media 
(10% serum). The viability of HA-BCA2 over-expressing cells was modestly but 
statistically significantly lower than control cells in all tested conditions (Figure 7).  
The relationship between BCA2 and Rab7 in HeLa cells.  
BCA2 and Rab7 have previously been shown to interact (13). We therefore decided to 
examine the sub-cellular localization of Rab7 in cells transiently transfected with HA-
BCA2. These cells were sequentially labeled for Rab7 and HA and were then imaged by 
confocal microscopy. The untransfected cells featured perinuclear clusters of Rab7 
positive vesicles whereas in HA-BCA2 over-expressing cells we observed an overall 
reduction in Rab7 fluorescence and in the number of the Rab7 positive vesicles (Fig. 8A). 
Contrary to previous reports in the literature (13) we did not find evidence of 
co-localization between the over-expressed BCA2 and Rab7 proteins.  
Others have previously reported co-localization between enhanced green fluorescence 
protein (EGFP) tagged Rab7 and BCA2 (13). We therefore examined the sub-cellular 
localization of HA-BCA2 and EGFP-Rab7 in transiently co-transfected cells. EGFP-Rab5, a 
marker of early endosomes with no reported links to BCA2, was studied in parallel. 
Whilst we observed some co-localization of BCA2 with EGFP-Rab7 in the perinuclear 
area, we also found that HA-BCA2 co-localized with EGFP-Rab5 on peripheral vesicles 
(Supplementary Figure S3). Since we were unable to demonstrate the specificity of BCA2 
and Rab7 co-localization with a dual over-expression approach, no further experiments 
were performed using the EGFP-Rab constructs. 
Rab proteins are delivered by chaperone proteins to membranes and interact with lipids 
via geranylgeranyl tails located at their C-terminus. (37). The reduction in vesicular 
Rab7 labeling seen in Figure 8A could have reflected a redistribution of Rab7 to the 
cytosol or alternatively a decrease in total Rab7 protein levels in the transfected cells. To 
distinguish between these two possibilities, Rab7 protein levels were examined in HA-
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BCA2 over-expressing and mock transfected HeLa cells after 5 and 60 min EGF 
incubation, as described in Figure 6. The data in Figure 8B demonstrate that Rab7 levels 
were unchanged by HA-BCA2 over-expression at either time point with EGF. This 
suggests that the loss of vesicular Rab7 seen by IF was the result of altered localization 
rather than a reduction in protein level.  
Biomarker and survival analysis 
KM Plotter (http://www.kmplot.com/) is an online analysis tool that integrates 
microarray expression data with clinical information from a large cohort of 10,188 
patient samples: 4,142 breast, 1,648 ovarian, 2,437 lung and 1,065 gastric cancer 
patients. Users can examine the impact on survival of different levels of gene expression 
for over 50,000 target genes (30). For this study the data were split into high and low 
expressing groups and survival curves were generated across all breast, ovarian, lung 
and gastric cancers. Survival was also examined in breast cancer analyses restricted 
according to estrogen receptor (ER) status, molecular subtype and HER2 expression. The 
hazard ratio for survival with 95% confidence intervals and logrank P value were 
automatically calculated for low vs. high expression.  
Survival curves generated with KM Plotter for high versus low BCA2 expression in breast 
cancer show that BCA2 significantly impacts on RFS in this disease and that survival 
effects are subtype dependant (Fig. 9). Plots for low versus high BCA2 expression show 
that breast cancers expressing high levels of BCA2 were associated with poorer 
prognosis: the hazard ratio (HR) for RFS across all tumours was 1.18, P=0.0046. 
Significantly reduced RFS was demonstrated in high BCA2 expressing breast cancers that 
were HER2 positive (HR=2.62, p=0.0021). In the HER2 over-expressing molecular 
subtypes luminal B and HER2, high BCA2 expression was also associated with reduced 
survival (Luminal B: HR=1.41, p=0.0018 and HER2: HR=1.54, p=0.044). Conversely, 
high levels of BCA2 in ER+ and HER2- disease were associated with improved patient 
prognosis (ER+: HR=0.73, p=0.0011 and HER-: HR=0.67, p=0.0055). 
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The effect of BCA2 on overall survival (OS) in lung, gastric and ovarian cancers was 
examined using KM Plotter to determine whether BCA2 was also a potential biomarker in 
cancers other than those of the breast (Fig. 10). High BCA2 expression was associated 
with poorer survival in gastric (HR=1.43, p=0.000035) and ovarian cancer (HR=1.24, 
p=0.0051). Conversely, high BCA2 expression appeared to be associated with increased 
overall survival in lung cancer, however, this narrowly missed reaching statistical 
significance (HR=0.86, p=0.051). 
Discussion  
Our results here demonstrating that BCA2 over-expression reduces total EGFR levels 
while inhibiting the receptor’s degradation initially appear to be contradictory. Others 
have shown that EGFR degradation is inhibited by the BCA2-Rab7 interaction (13) and 
supporting a relationship between the two proteins we found that HA-BCA2 
over-expression appeared to induce a failure of Rab7 membrane association. siRNA 
depletion of Rab7 has been shown to reduce the lysosomal degradation of EGFR while 
inducing a concomitant decrease in total levels of the receptor (7, 9). Thus the strongest 
hypothesis to explain our data is that over-expressed BCA2 sequesters Rab7 in the 
cytosol, preventing the GTPase from carrying out its endosomal function on the 
membrane. In this manner BCA2 over-expression produces cellular effects analogous to 
Rab7 depletion. Sequestration of interacting proteins is a documented effect of transient 
over-expression systems (38, 39).  
The finding that BCA2 over-expression inhibits EGFR trafficking is directly supported by 
some literature (13) but appears to be contrary to others (14, 15). Sakane and 
colleagues suggested that BCA2 over-expression accelerates ligand induced EGFR 
degradation in cells transfected with BCA2 and EGFR (14). However, the HEK293 cell line 
used did not readily degrade EGFR in response to EGF stimulation: after three hours the 
receptor levels were only reduced to 80% in the mock-transfected control cells. A 
separate experiment was performed in which cells were transfected with BCA2 plus 
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EGFR, ubiquitin and c-Cbl and here EGFR was extensively down-regulated in response to 
EGF stimulation. Under these conditions, EGFR degradation was inhibited in BCA2 over-
expressing cells compared with control, just as we have shown in Figure 4. Supporting 
our Rab7 sequestration hypothesis were further data from this study showing that a 
BCA2 RING mutant produced a greater inhibitory effect on EGFR degradation than wild-
type protein (14). The BCA2 RING mutant has been shown to lack E3-ligase (and 
autoubiquitination) activity (33) but, with an intact N-terminus, should still able to bind 
Rab7 (13). Enhanced inhibition of EGFR degradation by the RING mutant may therefore 
reflect intracellular accumulation of autoubiquination-deficient BCA2, leading to 
increased cytosolic sequestration of Rab7. 
Another BCA2 study that invites comparison with our research, is that conducted by 
Smith et al. (15). As in our experiments, the relationship between BCA2 and EGFR 
trafficking was investigated in a HeLa cell model. An siRNA approach was used for the 
studies and BCA2 depletion was shown to delay EGFR degradation. EGFR activation was 
also examined and here the BCA2 siRNA increased EGFR phosphorylation and promoted 
association of EGFR with the signalling protein SHC1. We extend this work by showing 
novel downstream signalling effects in a BCA2 over-expression system. Our findings 
indicate that EGF stimulation of BCA2 over-expressing cells gives rise to a reduced but 
more prolonged signalling response in MAPK (ERK1/2) and Akt pathways. The 
consequences of such a signalling pattern are not fully resolved, though they may be 
connected to the reduced cell viability seen in Figure 7. Our findings in Figure 6 are 
supported by the persistence of EGF in the (EEA1 positive) early endosomes of HA-BCA2 
over-expressing cells since EGFR is known to signal from this endocytic compartment 
(40). 
BCA2 over-expression (Figs. 4-7) and depletion (15) in the same cell line have now been 
shown to similarly influence EGFR trafficking. We hypothesise that in our studies BCA2 
over-expression produces a dominant negative phenotype, equivalent to that produced 
by protein depletion. This may be a result of disrupted stoichiometry between BCA2, 
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Rab7 and/or other interactors, an effect reported in the literature for other 
over-expressed proteins (38, 39).  
Since caspase 3-mediated cleavage of EGFR has been shown to occur concomitantly with 
reduced receptor degradation during apoptosis (41), our data in Figures 3 to 7 could 
alternatively be explained by cytotoxicity induced by over-expression e.g. by 
aggregate/aggresome formation. Aggresomes are cytoplasmic inclusions containing 
deposits of ubiquinated, often misfolded, proteins and are believed form when the 
production rate of aggregation-prone proteins exceeds proteasome capacity (42). 
Despite heterogeneity, the most commonly seen patterns of HA-BCA2 localization were 
large perinuclear and cytoplasmic inclusions. Such localization has also been seen in the 
literature (13, 27, 43) and may indicate a natural tendency for the protein to cluster 
and/or aggregate, especially at high expression levels. The accumulation of protein 
aggregates is known to affect cell signalling and to induce cytotoxicity (44, 45); it is a 
recognized potential limitation of transient transfection (46). The use of an inducible 
gene expression system, where the levels of BCA2 protein could be tuned, would 
potentially be more informative for further investigations. 
In vitro data presented here and in the literature suggest that exogenous manipulation 
of BCA2 expression may have context-dependent effects on cancer cell survival. We 
found that over-expression of BCA2 was well tolerated by MCF-7 cells but not by 
MDA-MB-231s. Interestingly, siRNA depletion of BCA2 has been shown to reduce cell 
growth in both the MCF-7 and MDA-MB-231 cell lines (17, 22), while pharmacological 
BCA2 inhibition results in differing cytotoxic effects: MCF-7 cells are sensitive to BCA2 
inhibitors but MDA-MB-231 are not (18). The effect of BCA2 over-expression on cell 
viability/proliferation has previously been examined in NIH3T3 mouse embryonic 
fibroblast cells and in these cells, proliferation was promoted by transfection with BCA2 
(17). We, however, show a reduction in HeLa cell viability upon BCA2 over-expression. 
The difference between these viability findings could relate to inter-cell line variation in 
the expression of BCA2 partner proteins, RTKs and/or endocytic regulators. The 
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cytotoxicity induced by BCA2 over-expression in HeLa cells is further evidence to support 
our hypothesis that over-expressing BCA2 produces a double negative phenotype that is 
akin to functional depletion of Rab7. siRNA depletion of Rab7 has been shown to 
promote cell death (9); sequestration of Rab7 by over-expressed BCA2 would therefore 
explain our findings. A network of the possible mechanisms linking BCA2 
over-expression with cell viability and EGFR regulation is presented in Supplementary 
Figure S4. 
Whilst the cells in this study were engineered to artificially over-express BCA2, high 
expression levels of this protein have been observed in breast cancer patients. Further 
experiments in breast cancer cell models would need to be performed to determine 
whether/to what extent our findings in HeLa cells apply to breast cancer specifically.  
In this study we have provided new in silico evidence that high levels of BCA2 may be 
associated with reduced relapse-free survival across all breast cancers. One previous 
study linked high levels of BCA2 to increased disease-free survival for regional 
recurrence and reduced lymph node metastasis (17). In this study by Burger et al. the 
relationship between BCA2 and the positive prognostic indicators was not thought to be 
a functional consequence of BCA2 expression. BCA2’s association with reduced 
recurrence and metastasis was attributed to the high incidence of BCA2 upregulation in 
ER+ breast cancer, the most readily treatable form of the disease. Our data however 
suggest that BCA2 may in fact have an independent functional impact on breast cancer 
prognosis rather than simply a bystander correlation with other positive prognostic 
indicators. This can be inferred as a positive relationship between BCA2 expression and 
survival is apparent in the ER+ group following stratification. Interestingly in the ER- 
cohort BCA2 appears to impinge on prognosis, although this effect did not reach 
statistical significance. 
The relationship between BCA2 expression and RFS in breast cancer has not been 
previously examined by subtype but was examined here. Our data indicated that high 
levels of BCA2 adversely affect survival in HER2 over-expressing cancers but was 
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associated with better prognosis in HER2- disease. The relationship between BCA2 and 
HER2 is further evident as high BCA2 expression impinged on RFS in the HER2-type and 
luminal B type breast cancers, both of which express high levels of the HER2 
oncoprotein. BCA2’s apparent link with HER2 in breast cancer survival may actually 
relate to the role of BCA2 in EGFR regulation rather than reflecting a direct relationship 
with HER2.  EGFR over-expression is most commonly seen in basal-type breast cancer 
but elevated levels of the receptor are often concomitant with HER2 positivity (47). 
Nonetheless a connection between BCA2 and HER2 has not been previously made in the 
literature and therefore may be a productive avenue for further research.  
We extended our in silico studies to examining the relationship between BCA2 expression 
and overall patient survival in lung, gastric and ovarian cancer. We demonstrated a 
novel, anatomical-context dependent relationship between BCA2 expression and OS. 
High BCA2 expression was associated with poorer prognosis in gastric and ovarian 
cancers but was associated with better prognosis in lung cancer. Exploration of the 
mechanism/s connecting BCA2 and survival in other cancers is beyond the scope of this 
study. However, our findings add to the body of evidence that the role of BCA2 in cancer 
is contingent on the biological context.  
Conclusions 
The accumulated data from our studies suggest that BCA2 has an important, context 
dependent role as a prognostic biomarker in cancer with both positive and negative 
contributions. Our findings indicate that the protein has a regulatory function in the 
trafficking and expression of EGFR, impacting on the signalling and viability of cancer 
cells. Developing a deeper understanding of BCA2’s context dependency will be essential 
for determining whether BCA2 is a potential therapeutic target in breast cancer. 
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 Figure 1: Comparative BCA2 expression analysis. A-C) From GOBO dataset of 51 normal and malignant 
breast cell lines. A) Log2 BCA2 expression levels across all the cell lines. Green arrows indicate the cell lines 
chosen for Western blotting analysis in 1D.  B) Mean Log2 BCA2 expression compared between basal A, B and 
luminal A subtypes. C) Mean Log2 BCA2 expression compared between triple negative, HER2 positive and 
hormone receptor positive disease. In A and B: Red = Basal A, Grey = Basal B and Blue = Luminal. D) 
Immunoblots of endogenous BCA2 and EGFR levels in a panel of cell lines. BCA2 protein levels quantified with 
ImageJ software, normalized to the tubulin loading control and their expression levels were calculated relative 
to MCF-10A cells.  
 Figure 2: Sub-cellular localization of HA-BCA2 in MCF-7, MDA-MB-231 and HeLa cells. Cells were 
transfected with HA-BCA2 and after 24 hr were fixed and immunolabeled for HA. Nuclei were counterstained 
blue with Hoechst. Blue arrowheads indicate vacuoles. Scale bars = 25 µm 
 Figure 3: Relative levels of EGFR, c-Met and TfR in mock transfected control and HA-BCA2 over-
expressing HeLa cells. A) Immunoblots for selected receptors in cells transfected with HA-BCA2 or mock 
transfected with an empty control vector. B-D) Protein expression was quantified with ImageJ software. Results 
from three independent, experiments carried out in duplicate are shown. Error bars represent 95% confidence 
intervals. ** p≤0.01. *** p≤0.001. E and F) Confocal microscopy images of EGFR in HA-BCA2 over-expressing 
HeLa cells. HA-BCA2 transfected cells were serum starved for 60 min then either E) stimulated with 20 ng/mL 
EGF for 15 min or F) incubated with EGF Alexa 488 for 30 min on ice. Cells were then fixed and immunolabeled 
for HA-BCA2 (red) and (in E only) for EGFR (green). Nuclei were stained blue with Hoechst. Representative 
images from two independent, duplicate experiments are shown. Scale bars = 50 µm. Arrowheads indicate 
examples of HA-BCA2 transfected cells.  
 Figure 4: EGFR and EGF degradation in HA-BCA2 over-expressing HeLa cells. A) HA-BCA2 and mock 
transfected HeLa cells were serum starved for 60 min then stimulated with 20 ng/ml EGF for 0 or 60 min. Cell 
lysates were collected from three independent, triplicate experiments. Western blotting was performed for 
EGFR and HA. Representative blot of a single experiment is shown. B) Band intensities were quantified using 
ImageJ software. Error bars represent 95% confidence intervals. * p≤0.05. ** p≤0.01. C and D) Confocal 
microscopy images of endocytosed fluorescent EGF and Transferrin (Tf) in HA-BCA2 over-expressing HeLa 
cells. HA-BCA2 transfected cells were incubated with 0.5 µg/mL Alexa-488 EGF or 8 µg/mL Alexa-488 Tf (both 
green) for 15 OR 60 min before being fixed and immunolabeled for HA (red). Nuclei were stained blue with 
Hoechst. Scale bar = 50 µm. Arrowheads indicate examples of HA-BCA2 transfected cells. 
 
 
  
 Figure 5: Endocytic profile of HA-BCA2 over-expressing HeLa cells ± EGF. HA-BCA2 transfected cells 
were incubated with 0.5 µg/mL Alexa-555 EGF (red) for 0 or 60 min before being fixed. A) Sequential 
immunolabeling of HA-BCA2 and EEA1 (early endosomes, blue). B) Co-incubation of Alexa-555 EGF and Tf-647 
(recycling endosomes, blue) and immunolabeling for HA-BCA2.  C) Sequential immunolabeling of HA-BCA2 and 
LAMP2 (late endosomes/lysosomes, blue). D) Sequential immunolabeling of HA-BCA2 and cathepsin D 
(lysosomes, blue). Scale bar = 50 µm. White arrowheads indicate examples of HA-BCA2 transfected cells. Inset 
is merge of red and blue channels to show co-localisation (purple) between endocytic markers and EGF. Green 
arrowheads indicate examples of co-localisation. 
  
 Figure 6:  EGFR activation and signalling in HA-BCA2 over-expressing HeLa cells following. HA-BCA2 
and mock transfected cells were serum starved for 60 min then stimulated with 20 ng/mL EGF for 5 or 60 min. 
Cell lysates were collected from three independent experiments. A) Western blotting was performed for EGFR, 
pEGFR (Tyr1068), AKT (Ser473), pAKT, ERK, pERK (Thr202/Tyr204) and HA. Band intensities were quantified 
using ImageJ software and are presented as the amount of pEGFR normalized to total EGFR, amount of pEGFR 
normalized to total AKT, amount of pAKT normalized to total AKT and amount of pERK normalized to total ERK. 
B) Relative amount of phosphorylated proteins at 5 min. C) Relative amount of phosphorylated proteins at 60 
min. Error bars represent 95% confidence intervals. ** p ≤ 0.01. *** p ≤ 0.001. 
 
 
Figure 7: The effect of BCA2 over-expression on the viability of transiently transfected HeLa cells. 
HA-BCA2 or Mock transfected cells were either serum-starved (0.5% FBS) or grown for 48 hr in the presence 
of 10% FBS or 20 ng/ml EGF in 0.5% serum-containing media. Cell viability was analyzed by CellTitre- Blue™ 
assay. Results from three independent, triplicate experiments were normalized to mock transfected control 
cells grown in FBS. Error bars represent 95% confidence intervals. ** p≤0.001. 
  
 Figure 8: Rab7 sub-cellular localization and expression levels in HA-BCA2 over-expressing HeLa 
cells. A) Confocal microscopy of HA-BCA2 (red) over-expressing cells following sequential immunlabeling for 
Rab7 (green) then HA (Red). Nuclei were stained with Hoechst (blue). Arrowheads indicate examples of HA-
BCA2 transfected cells. Scale bars = 50 µm. B) Immunoblot showing Rab7 levels in mock transfected and HA-
BCA2 over-expressing HeLa following EGF stimulation. HA-BCA2 and mock transfected cells were serum 
starved for 60 min then stimulated with 20 ng/mL EGF for 5 or 60 min. Cell lysates were prepared from three 
independent experiments (repurposed from experiment in Figure 6) and probed for HA and Rab7. 
  
 Figure 9: Kaplan-Meier survival curves for high vs. low BCA2 mRNA expression in breast cancer 
created using KM Plotter (30). Probability of relapse free survival in high (red) or low (black) BCA2 
expressing breast cancer is compared. A) Survival across all tumours. B) Survival in ER+ vs. ER- disease. C) 
Survival in HER2+ vs. HER2- disease. D) Survival stratified according to molecular subtype. 
 
 
 
 
 
 
 Figure 10: Kaplan-Meier survival curves for high vs. low BCA2 mRNA expression in lung, gastric and 
ovarian cancer created using KM Plotter (30). Probability of overall survival in high (red) or low (black) 
BCA2 expressing is compared in A) lung cancer B) gastric cancer and C) ovarian cancer. 
 
Supplementary Materials and Methods 
siRNA depletion of BCA2 
siRNA sequences: Dharmacon ON-TARGET plus SMARTpool siRNA RNF115 (#L-006974-
00-0005, Fisher Scientific) and non-targeting siRNA control (GFP):  
5’-GGCUACGUCCAGGAGCGCAdTdT-3’ (MWG) 
MCF-7 cells (250,000) were seeded in 6-well plates and incubated overnight in RPMI 
supplemented with 10% FBS. The following day the transfection mixture was prepared 
by mixing: 2.4 µL Dharmafect1 transfection reagent in 237.6 µL of Serum Free Media 
(SFM) and incubating at room temperature for 5 min. Meanwhile 12 µL of 5 µM siRNA 
(either non-targeting GFP siRNA or BCA2 SMARTpool siRNA) was mixed with 228 µL 
SFM. The diluted Dharmafect1 was then added to the diluted siRNA and the mixture was 
incubated at room temperature for 30 min at room temperature. The cell media was 
aspirated and replaced with 1920 µL of compete media. After 30 min incubation 480 µL 
transfection mixture was added to each well, giving a final siRNA concentration of 25 nM. 
Cells were incubated with the siRNA for 48 hr before further experiments were 
performed. 
Co-transfection of HA-BCA2 and EGFP-Rab constructs 
Plasmid constructs: pEGFP-C1 containing Rab7 and Rab5 were used in the double-
transfection / co-localisation experiments (20).  
0.5 µg of pHA-BCA2 and 0.5 µg of EGFP-Rab5 or EGFP-Rab7 were used to transfect the 
cells according to the Fugene 6 transfection protocol outlined in Materials and Methods.    
Dual-Immunofluorescence labelling of HA and BCA2 in transfected HeLa cells 
HeLa cells were transfected with HA-BCA2 and subjected to single and dual-
immunofluorescence labelling for HA and for BCA2 according to the protocols for these 
procedures outlined in Materials and Methods. The anti-BCA2 (#SAB2500854, Sigma 
Aldrich) antibody was used at a dilution of 1:5000.   
Supplementary Figures 
 
 
Figure S1: BCA2 depletion increases EGFR levels in MCF-7 cells. A) Immunoblots for BCA2 and selected 
recptors in cells treated with BCA2 SMARTpool siRNA or GFP non-targeting control siRNA. B, C and D) Relative 
protein expression was quantified with ImageJ software and normalised to tubulin loading control. Results from 
three independent, single experiments are shown. Error bars represent 95% confidence intervals. * statistical 
significance p ≤ 0.05.  
	
	
	
	
	
	
	
 Figure S2: Anti-HA and Anti-BCA2 IF in HA-BCA2 Transfected MCF-7 cells. A) Sequential double IF 
was performed in HA-BCA2 transfected cells using the goat anti-BCA2 antibody and mouse anti-HA. 
Nuclei were counterstained with Hoechst. B) Separate anti-HA and anti-BCA2 IF was performed. Scale 
bars = 25 µm 
	
	
 Figure S3: Confocal microscopy images of HeLa cells cotransfected with HA-BCA2 and selected 
EGFP-tagged Rab proteins. Cells were transiently transfected with HA-BCA2 and A) EGFP-Rab7, B) 
EGFP-Rab5. IF was performed for HA (red) and nuclei were stained with Hoechst (blue). Blue arrowheads 
indicate colocalisation. Scale bars = 50 µm. 
 Figure S4: Summary of the possible mechanisms to explain BCA2 mediated effects on cell survival 
and on total receptor levels and trafficking. Novel or confirmatory BCA2 findings from our studies are 
underlined and in bold. 
 
	
